Cencora, Inc. logo

Cencora, Inc. (COR)

Market Closed
11 Aug, 20:00
NYSE NYSE
$
333. 87
+8.87
+2.7292%
$
59.59B Market Cap
23.39 P/E Ratio
2.4% Div Yield
1.37M Volume
11.93 Eps
$ 325
Previous Close
Add Transaction
Day Range
324.3 333.94
Year Range
244.82 377.54
Want to track COR and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) Reports Next Week: Wall Street Expects Earnings Growth

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks | 2 years ago
Why Cencora (COR) is a Top Value Stock for the Long-Term

Why Cencora (COR) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 years ago
Why Cencora (COR) is Poised to Beat Earnings Estimates Again

Why Cencora (COR) is Poised to Beat Earnings Estimates Again

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks | 2 years ago
Cencora (COR) Stock Nosedives: Here's What Caused the Decline

Cencora (COR) Stock Nosedives: Here's What Caused the Decline

Cencora (COR) shares declined on Jun 27, following an unfavorable ruling from the Supreme Court related to a previously settled litigation. Here we discuss the key factors that likely led to the decline.

Zacks | 2 years ago
Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Drug Distributor Cencora Falls; Blame Walgreens, Not The Supreme Court

Cencora stock and other drug distributors fell on Wednesday, hit by Walgreens results, not the ruling that killed an opioid settlement.

Investors | 2 years ago
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks | 2 years ago
Cencora: Long-Term Compounder With Mouth-Watering Economics

Cencora: Long-Term Compounder With Mouth-Watering Economics

COR shares have advanced 13% since my last publication, adding conviction to the long-term thesis. The company has exceptional economic characteristics with abnormally high ROICs and negative working capital benefits. I have updated my price objectives to $270-$285 with a long-term intrinsic valuation of over $360 per share.

Seekingalpha | 2 years ago
Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

Cencora (COR) Gains 13.2% YTD: What's Driving the Stock?

Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.

Zacks | 2 years ago
Here's Why Cencora (COR) is a Strong Value Stock

Here's Why Cencora (COR) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks | 2 years ago
Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Reasons to Hold Cencora (COR) Stock in Your Portfolio for Now

Cencora (COR) continues to gain traction from the robust U.S. Healthcare Solutions segment. However, stiff competition is a woe.

Zacks | 2 years ago
Cencora notifies individuals about data stolen earlier this year

Cencora notifies individuals about data stolen earlier this year

U.S. drug distributor Cencora has notified affected individuals that their personal and highly sensitive medical information was stolen during a cyberattack and data breach earlier this year, the company said on Friday.

Reuters | 2 years ago
Why Cencora (COR) is a Top Value Stock for the Long-Term

Why Cencora (COR) is a Top Value Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Zacks | 2 years ago
Loading...
Load More